# CareDx, Inc. (CDNA)

> Source: Nexqual · https://nexqual.com/CDNA · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, CareDx, Inc. (CDNA), nexqual.com/CDNA" · informational, not investment advice.

**Price:** USD 69.16 (-2.23% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 70.74 · day 66.84–71.51 · 52w 14.03–72.71 · market cap $3.58B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $458M, net income $111M (24.2% margin) (SEC filings).
- Valuation: P/E 32.2x (avg 23.1x at the last 1 fiscal year-ends).
- 1 of 80 tracked superinvestors hold CDNA (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 64.17 (range 46–80).
- Total return with dividends: 1Y +370.5% vs S&P 500 +14.9%; 5Y -4.0% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.26, revenue estimate $122M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $296M | $322M | $280M | $334M | $380M | $458M |
| Operating income | -$29.7M | -$77.2M | -$203M | $40.8M | -$30.8M | $108M |
| Net income | -$30.7M | -$76.6M | -$190M | $52.5M | -$21.4M | $111M |
| EPS (diluted) | -$0.59 | -$1.44 | -$3.54 | $0.93 | -$0.40 | — |
| Operating margin | -10.0% | -24.0% | -72.5% | 12.2% | -8.1% | 23.6% |
| Net margin | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% | 24.2% |
| Revenue growth | +54.2% | +8.6% | -12.9% | +19.1% | +13.8% | — |
| Cash + short-term investments | $348M | $293M | $235M | $261M | $177M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 32.2x · P/S 7.8x · P/B 8.4x · Earnings yield 3.10%
P/E at fiscal year-ends: Dec 2024 23.1x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold CDNA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.03% | $17.1M | Added +4.0% |

## Analysts
Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 64.17 (low 46, high 80).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Target raised | Buy | $65 → $80 |
| 2026-09-24 | BTIG | Target raised | Buy | $60 → $74 |
| 2026-09-02 | Canaccord Genuity | Initiated | Buy | $65 |
| 2026-08-06 | BTIG | Target raised | Buy | $45 → $60 |
| 2026-07-31 | HC Wainwright & Co. | Reiterated | Neutral | $46 |
| 2026-07-16 | BTIG | Target raised | Buy | $28 → $45 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +370.5% | -4.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +373.0% | -0.8% |
| Volatility (annualized) | 68.7% | 78.3% |
| Max drawdown | -23.6% (Jan 2026→Apr 2026) | -93.1% (Oct 2021→Oct 2023) |

## Peers (Diagnostics & Research)
VCYT (Veracyte, Inc.) USD 46.04 -0.39% · ADPT (Adaptive Biotechnologies Corpor) USD 24.41 -3.63% · BLLN (BillionToOne, Inc.) USD 105.68 +0.96% · SHC (Sotera Health Company) USD 18.13 +2.03% · RDNT (RadNet, Inc.) USD 70.26 +2.70% · GRAL (GRAIL, Inc.) USD 127.06 -4.18%

## More
Full page: https://nexqual.com/CDNA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Testing services revenue | $99.9M | 75.7% | +61.1% |
| Patient and digital solutions revenue | $19.2M | 14.6% | +50.1% |
| Product revenue | $12.8M | 9.7% | +8.1% |
| Total revenue | $131.9M | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $126.6M | 96.0% | +55.1% |
| Rest of World | $5.3M | 4.0% | +5.6% |
| Total revenue | $131.9M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 30% of revenue from unnamed direct customers (10-Q, filed 2026-07-30).

## Company outlook (8-K filed 2026-07-30)

- "Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.26 | $0.19 | +35.6% | $122.0M | 6 |
| Next quarter (ends 2026-12-31) | $0.23 | $0.17 | +36.3% | $123.5M | 6 |
| Current fiscal year (ends 2026-12-31) | $1.20 | $0.93 | +28.3% | $495.1M | 6 |
| Next fiscal year (ends 2027-12-31) | $1.29 | $1.13 | +13.8% | $526.0M | 6 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-10-29): ±19.2%; last 8 reports averaged ±13.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 85.0% | ±19.2% |
| 2026-12-18 | 56 | 70.8% | ±22.3% |
| 2027-02-19 | 119 | 63.7% | ±28.9% |
| 2027-03-19 | 147 | 64.3% | ±32.4% |
| 2027-05-21 | 210 | 62.8% | ±37.6% |
| 2027-11-19 | 392 | 58.6% | ±47.3% |